Clinical Trial Update: A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) [Phase 2]

View source ↗

Summary

This document describes an ongoing Phase II trial investigating perioperative adebrelimab in combination with XELOX for patients with resectable locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Adebrelimab (SHR-1316) (adebrelimab)
• XELOX (capecitabine + oxaliplatin) (capecitabine + oxaliplatin)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Adebrelimab (SHR-1316), XELOX | Phase 2 | Status: RECRUITING